## Appl. No. 09/991,796 Amdt. dated Reply to Office action of November 4, 2005

#### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

Claim 1. (currently amended) An isolated biopolymer marker which evidences a link to Type II diabetes selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4.

#### Claims 2-38. (cancelled)

Claim 39. (withdrawn-currently amended) A method for determining the presence of an isolated <u>a</u> biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 comprising:

- (a) obtaining a sample from a patient;
- (b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum spectral profiles of said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 to mass spectrum spectral profiles of peptides obtained and analyzed from said sample; and

# Appl. No. 09/991,796 Amdt. dated Reply to Office action of November 4, 2005

(c) confirming the presence of said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 in said sample displaying a peak profile at about 1630 daltons in said mass spectrum profile by identifying a mass spectral profile having an ion peak at about 1630 daltons;

wherein the presence of said <del>isolated</del> biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 is indicative of a link to Type II diabetes.

Claim 40. (withdrawn-currently amended) The method of claim 39, wherein [[the]] <u>said</u> sample is an unfractionated body fluid or tissue sample.

Claim 41. (withdrawn) The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 42. (withdrawn-currently amended) The method of claim 39, wherein said mass spectrometric analysis is selected from the group of mass spectrometry formats consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

## Appl. No. 09/991,796 Amdt. dated Reply to Office action of November 4, 2005

Claims 43. (withdrawn) The method of claim 39, wherein said patient is a human.

Claim 44. (withdrawn-currently amended) A kit for determining the presence of an isolated <u>a</u> biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 comprising: (a) a peptide selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4, and (b) an antibody that binds to said peptide in a sample from a patient.

Claim 45. (withdrawn) The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46. (withdrawn) The kit of claim 44, wherein said antibody is labeled.